Beyond Air, Inc. (XAIR) subsidiary NeuroNOS appoints Dan Shechtman to SAB
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board
April 15, 2025 4:05 PM EDTBOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and Alzheimers disease (AD)conditions, and a subsidiary of Beyond Air (NASDAQ: XAIR), is proud to announce the appointment of Nobel Prize laureate, Professor Dan Shechtman, to its Scientific Advisory Board (SAB).
We are delighted to welcome Professor Shechtman to our Scientific Advisory Board, said Amir Avniel, CEO of NeuroNOS. The addition of Professor Shechtman, alongside Professor Roger Kornberg from Stanford University, brings unparalleled scientific expertise to our... More
